Alerts will be sent to your verified email
Verify Email
GUJTHEM
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
Gujarat Themis Biosyn Ltd. manufactures and markets bulk drugs and intermediates, specializing in anti-tuberculosis and antibiotic products. The company focuses on fermentation-based APIs and caters to domestic and international pharmaceutical markets.
Guj. Themis Biosyn major competitors are Concord Biotech, Medicamen Biotech, Orchid Pharma, Zota Health Care, Unichem Lab, Gufic Biosciences, Sequent Scientific.
Market Cap of Guj. Themis Biosyn is ₹4,608 Crs.
While the median market cap of its peers are ₹4,407 Crs.
Guj. Themis Biosyn seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | Mar | Sep Dec | ||||||||||||||||
| Investor Presentation | May Aug Nov | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Jun Dec | |||||||||||||
| Conference Call | Mar Sep | Sep Dec | Sep | |||||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
